Industry
BioCentury
I-DXd withdrawal thins October PDUFA calendar
BIOCENTURY | DATA BYTEI-DXD WITHDRAWAL THINS OCTOBER PDUFA CALENDARFive FDA decisions remain after BLA withdrawal and two sNDA approvals
The latest biotech and pharma news from the trade press, updated every hour and linked straight to the publisher. Follow funding, clinical, deals and more. Every story links straight to its publisher.
Industry
BioCentury
BIOCENTURY | DATA BYTEI-DXD WITHDRAWAL THINS OCTOBER PDUFA CALENDARFive FDA decisions remain after BLA withdrawal and two sNDA approvals
Industry
BioCentury
BIOCENTURY | DEALSNOVO GETS SHOT AT WEEKLY OBESITY PILL AS HENGRUI GETS ANOTHER MNC DEALNovo adds once-weekly oral GLP1R/GIPR dual agonist for $300M up front
Industry
BioCentury
BIOCENTURY | POLITICS, POLICY & LAWBEAM LAWSUIT ACCUSES YOLTECH AND SERAPHA OF TECH THEFTYolTech CEO ‘categorically rejects’ accusations
Funding
BioCentury
BIOCENTURY | PRODUCT DEVELOPMENTFOUR-YEAR DATA RAISE DURABILITY QUESTIONS FOR UNIQURE’S HUNTINGTON GENE THERAPYSmaller effect on composite endpoint clouds outlook, while functional capacity results preserve case for approval
Industry
Nature Reviews Drug Discovery
Clinical N Nature Medicine
Clinical
BioCentury
BIOCENTURY | DEALSASTRAZENECA BUYS STAKE IN SUMMIT, PLANS COMBO TRIALS PAIRING ADCS WITH BISPECIFIC$2B equity investment signals commitment to testing conjugated therapies, including CLDN18.2-targeted ADC, with ivonescimab
Industry
Inside Precision Medicine
First-in-class triple agonist retatrutide produced nearly 19% average weight loss in people with obesity and type 2 diabetes, a population historically harder to treat. The post Triple Agonist Retatrutide Pushes Weight Loss to New Levels in Type 2 Diabetes appeared first on Insid…
Research
GEN
Merck agreed to pay SciBrunch up to $2.13 billion consisting of $400 million upfront and the remainder in payments tied to achieving milestones across multiple indications. The post Merck, SciBrunch Launch Up-to-$2.13B Collaboration to Develop Preclinical KRAS-Inhibiting Molecula…
Regulatory
FDA Press Announcements
The U.S. Attorney’s Office for the Middle District of Florida and the Criminal Division of the U.S. Department of Justice today announced federal charges against Swapnadip Roy, 33, and Vicky Ramancha, 37, both Indian nationals.
Industry B BioPharm International
Novo Nordisk licenses a once-weekly oral GLP-1/GIP candidate, uniQure reports 48-month Huntington’s disease data, and AstraZeneca invests $2 billion in Summit Therapeutics.
Agriculture
CropLife
CPDA’s 2026 annual meeting brought industry leaders together in Dallas for networking, awards, regulatory updates and a look at organizational growth. The post CPDA 2026 Annual Meeting Highlights Growth, Leadership and Industry Collaboration appeared first on CropLife.
Industry
MedCity News
AstraZeneca’s equity investment in Summit Therapeutics comes with plans for clinical trial collaborations. The deal brings AstraZeneca into a growing group of pharmaceutical companies testing the pairing of antibody drug conjugates with PD-1/VEGF bispecific antibodies, a drug com…
Manufacturing
C&EN Pharmaceuticals
Here’s what we’re watching in the chemical and pharmaceutical industries this week
Industry P Pharmaceutical Executive
New U.S. guidance carves out tariff exemptions for specialty pharmaceuticals, Pharming's Fabrice Chouraqui steps down as CEO amid a board rift, and a dealmaking roundup covers Hengrui Pharma's licensing agreement with Novo Nordisk and AstraZeneca's investment in Summit Therapeuti…
Industry
BioPharma Dive
Beam claimed a former scientist stole confidential information and quietly spun up a rival rare disease treatment at YolTech Therapeutics. Serapha Bio, which licensed that therapy, denies the charges.
Manufacturing B BioProcess International
When scientifically justified and embedded within a comprehensive control framework, reduced-volume bioburden testing represents a practical and defensible approach for low-volume, high-value cell and gene therapies.
Software L Latch Bio
A verifiable benchmark for taxonomic and functional profiling, microbial ecology, and host–microbiome analysis
Industry
STAT Biotech
The gene-editing company Beam Therapeutics is alleging that one of its scientists stole intellectual property and used it to co-found a Chinese company that made a deal with VC firms.
Industry A Applied Clinical Trials
RWE is finding a role earlier in drug development than ever before, but the data quality, integration, and organizational alignment required to make it regulatory-grade are still catching up to the ambition.
Manufacturing B BioProcess International
Biosimilar sponsors will need to adopt earlier and more integrated planning approaches to capitalize on opportunities created by streamlined regulatory frameworks.
Industry
GEN
The consortium aims to address antibody development bottlenecks by creating standardized datasets and AI models that support earlier risk detection and more informed candidate selection. The post Ginkgo Datapoints, Apheris Announce Founding Members of Antibody Developability Cons…
Manufacturing
Drug Delivery Business
BD (NYSE:BDX) is celebrating the 70th birthday of its major manufacturing facility in Utah, which the company said produces billions of molded components each year. Located in the town of Sandy just south of Salt Lake City, the site was founded in 1956 under Deseret Pharmaceutica…
Regulatory P Pharmaceutical Executive
New U.S. guidance exempts orphan drugs, nuclear medicines, cell and gene therapies, and other specialty products from the 100% pharmaceutical tariff when imported from 19 named countries.
Industry B BioPharm International
Novo gains global rights, excluding Greater China, to HRS-1596, a phase 1-ready GLP-1/GIP dual receptor agonist that Hengrui says has potential for once-weekly oral dosing in obesity and type 2 diabetes.
Manufacturing B BioProcess International
Sanofi says integrated continuous purification is a “universal solution” for downstream processing as it prepares for clinical production in 2027.
Industry
Drug Discovery and Development
After more than a year of threats and six months after President Donald Trump signed a national-security proclamation, U.S. tariffs on imported patented medicines and their ingredients expanded Sept. 29 to mid-sized and smaller drugmakers that were left off the first company list…
Agriculture E European Seed
MAS Seeds breeding combines climate modelling, genomics, advanced phenotyping and field testing to anticipate future growing conditions. The approach aims to deliver maize and sunflower hybrids with more reliable performance across changing environments. The post From Data to the…
Research
C&EN Pharmaceuticals
The teams say this method is more accessible and cost efficient
Clinical B BioPharm International
NouvSight001 isn't limited to the RPE65-mutation subset current gene therapy treats, potentially reaching more of the 1.5 million with RP worldwide.
Industry
BioPharma Dive
The deal, which hands Novo a challenger to Lilly’s market-leading Zepbound, comes as the Danish drugmaker looks to calm investor fears about its future.
Funding
MedTech Dive
Citing market uncertainty, the smart ring maker plans to delay a public offering that it had expected to raise up to $2.2 billion.
Funding
MedTech Dive
The venture capital firm expects to launch up to eight new medtech ventures over the next five years.
Industry
Fierce Pharma
From Data Rich to Decision Ready in Life Sciences pesurya Tue, 09/29/2026 - 11:39
Industry
BioPharma Dive
Analysts guessed that investors wanted to see stronger durability results at a four-year check-in of the key trial supporting a potential approval of "AMT-130."
Industry
GEN
Chemotherapies frequently cause cancer cells to enter senescence, but do not fully eliminate these cells. Therefore, it is useful to target these therapy-induced senescent cells with senolytics that eliminate them. The post How Cells Respond Differently to a Cancer-Causing Gene a…
Clinical B BioPharm International
Updated 36-month data in 15 high-dose patients showed 80% slowing on cUHDRS, while the 48-month cUHDRS result did not reach statistical significance. uniQure attributes the gap to attrition in the external control, and the FDA is reviewing a BLA based on the 36-month data.
Agriculture
CropLife
RDO demonstrates connected equipment, precision technology, and local support solutions to help farmers maximize efficiency all season. The post RDO Showcases Smarter Equipment, Precision Tech and Support at Big Iron appeared first on CropLife.
Industry
Fierce Biotech
There Is No Such Thing as a Typical Biotech pesurya Tue, 09/29/2026 - 11:06
Industry
TechCrunch Biotech and Health
Uhura Bionics, part of the Startup Battlefield 200 at TechCrunch Disrupt, wants to replace flat, robotics voice devices with one that carries emotions.